PSMA PET测定的肿瘤体积作为卡巴他赛治疗前列腺癌患者的预后生物标志物
回顾性评估32例接受卡巴他赛二线化疗的转移性去势抵抗性前列腺癌患者,于治疗前8周内行68Ga-PSMA PET/CT并测量全身PSMA总肿瘤体积(PSMA-TV)。中位随访12个月,28例进展、18例死亡;基线PSMA-TV与无进展生存(PFS)和总生存(OS)显著相关,多变量分析中PSMA-TV仍是OS的独立预测因子。
要点
- 基线PSMA-TV与PFS和OS显著相关(P=0.035和P=0.002)。
- PSMA-TV低体积组中位PFS 21周 vs 高体积组12周(HR 0.33,P=0.017)。
- PSMA-TV低体积组中位OS 24个月 vs 高体积组8.5个月(HR 0.21,P=0.002)。
核心结论
- PSMA PET/CT测得的总肿瘤体积是卡巴他赛治疗患者的预后生物标志物,治疗前高PSMA-TV与更短PFS和OS相关。
研究设计与样本
- 回顾性评估所有在开始卡巴他赛治疗前8周内行PSMA PET/CT的转移性去势抵抗性前列腺癌患者,共纳入32例,接受中位6个周期卡巴他赛(范围2-10)。
- 测量每例患者全身PSMA总肿瘤体积(PSMA-TV),并记录前列腺特异性抗原、血红蛋白、乳酸脱氢酶和碱性磷酸酶等指标。
- 采用log-rank cutoff finder确定PSMA-TV最佳截断值,生存分析采用Cox回归和Kaplan-Meier法。
主要发现
- 中位随访12个月后,28例出现疾病进展,18例死亡。
- 基线PSMA-TV与PFS和OS显著相关(P=0.035和P=0.002)。
- PFS的最佳PSMA-TV截断值为515 mL,OS的最佳PSMA-TV截断值为473 mL。
- 低体积组较高体积组PFS更长:中位PFS 21周 vs 12周(HR 0.33,P=0.017);低体积组较高体积组OS更长:中位OS 24个月 vs 8.5个月(HR 0.21,P=0.002)。
- 多变量分析中,PSMA-TV仍是OS的独立预测因子(P=0.016)。
关键数值与推荐
- PFS的PSMA-TV最佳截断值为515 mL,OS的PSMA-TV最佳截断值为473 mL。
- 低体积组中位PFS 21周 vs 高体积组12周(HR 0.33,P=0.017)。
- 低体积组中位OS 24个月 vs 高体积组8.5个月(HR 0.21,P=0.002)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The aim of this study was to evaluate the prognostic value of 68 Ga-labeled prostate-specific membrane antigen (PSMA) PET/CT in metastatic castration-resistant prostate cancer patients receiving second-line chemotherapy with cabazitaxel. METHODS: All patients with metastatic castration-resistant prostate cancer who underwent a PSMA PET/CT within 8 weeks before initiating the cabazitaxel treatment were retrospectively evaluated. The whole-body PSMA total tumor volume (PSMA-TV) was measured for each patient. Other factors such as prostate-specific antigen, hemoglobin, lactate dehydrogenase, and alkaline phosphatase were recorded. A log-rank cutoff finder was used to define the PSMA-TV optimal cutoff. Survival analyses were performed using Cox regression and Kaplan-Meier methods. RESULTS: In total, 32 patients were included, receiving a median of 6 cycles of cabazitaxel (range, 2-10). After a median follow-up of 12 months, 28 patients presented disease progression, and 18 died. Baseline PSMA-TV presented a significant association with progression-free survival (PFS) and overall survival (OS; P = 0.035 and P = 0.002, respectively). Optimal PSMA-TV cutoffs were 515 mL for PFS and 473 mL for OS. Patients with low volume presented longer PFS and OS than those with high volume: median PFS, 21 versus 12 weeks, respectively (hazard ratio, 0.33; P = 0.017); and median OS, 24 versus 8.5 months, respectively (hazard ratio, 0.21; P = 0.002). On the multivariable analyses, PSMA-TV remained an independent predictor of OS ( P = 0.016). CONCLUSION: Our results show that total tumor volume measured on PSMA PET/CT is a prognostic biomarker in patients treated with cabazitaxel. High PSMA-TV before treatment initiation is associated with shorter PFS and OS.
引用
- Shagera QA, Karfis I, Sideris S, et al. Tumor Volume on PSMA PET as a Prognostic Biomarker in Prostate Cancer Patients Treated With Cabazitaxel. Clin Nucl Med. 2023. PMID: 37385221. doi:10.1097/RLU.0000000000004763
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。